Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes

Pharmacogenetics and Genomics

Volumn 18, Issue 8, 2008, Pages 699-707

  Ritt, Martin ^a   Ott, Christian ^a   Delles, Christian ^a   Schneider, Markus P ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Basal nitric oxide activity; Diabetes; G894T polymorphism of NOS3; Oxidative stress; Renal vasculature

Indexed keywords

4 AMINOHIPPURIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ASCORBIC ACID; ATENOLOL; CEBION FORTE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; METOPROLOL; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THREONINE; UNCLASSIFIED DRUG; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NOS3 PROTEIN, HUMAN; THYMINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG INFUSION; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY CIRCULATION; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; ANALYSIS OF VARIANCE; BLOOD; BODY MASS; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEMODYNAMICS; HOMOZYGOTE; MIDDLE AGED; PATHOPHYSIOLOGY;

ALLELES; ANALYSIS OF VARIANCE; ARGININE; ASCORBIC ACID; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; FEMALE; GENOTYPE; GUANINE; HEMODYNAMICS; HOMOZYGOTE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL PLASMA FLOW; THYMINE; TRIGLYCERIDES;

EID: 55749104951     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32830500b1     Document Type: Article

References (43)

1. Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001; 37:744-748.
2. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997; 30:311-333.
3. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18:364-366.
4. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113:1708-1714.
5. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997; 100:2146-2152.
6. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003; 284:F1121-F1137.
7. Rangan GK, Wang Y, Harris DC. Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 2001; 12:1696-1705.
8. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161:239-248.
9. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17:2664-2669.
10. Shin Shin Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, et al. Relations between eNOS glu298asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract 2004; 65:257-265.
11. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS glu298asp polymorphism with end-stage renal disease. Hypertension 2002; 40:535-540.
12. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 2003; 244:113-118.
13. Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW. Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1794-1800.
14. Mollsten A,Wessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, et al. Glu298asp and NOS4ab polymorphisms in diabetic nephropathy. Ann Med 2006; 38:522-528.
15. Delles C, Schneider MP, Oehmer S, Fleischmann I, Fleischmann EF, Schmieder RE. Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. Nephrol Dial Transplant 2004; 19:2513-2518.
16. Schneider MP, Klingbeil AU, Delles C, Schmidt BM, John S, Schmieder RE. Vitamin C augments the renal response to L-arginine in smokers. Nephrol Dial Transplant 2003; 18:1512-1517.
17. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945; 24:388-404.
18. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 glu298asp variation in human endothelium: altered caveolar localization and impaired response to shear. Federation Am Soc Exp Biol J 2007; 21:2655-2663.
19. Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol 2005; 46:1101-1109.
20. Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, et al. Glu298asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90:1153-1158.
21. Philip I, Plantefeve G, Vuillaumier-Barrot S, Vicaut E, LeMarie C, Henrion D, et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation 1999; 99:3096-3098.
22. Sandrim VC, De Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 2006; 189:241-246.
23. Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno H Jr, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 2006; 24:2393-2397.
24. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, et al. A common variant of endothelial nitric oxide synthase (glu298asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001; 32:735-740.
25. Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, et al. Atherosclerosis and the glu298asp polymorphism of the eNOS gene in white patients with end-stage renal disease. Am J Hypertens 2005; 18:1549-1555.
26. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase (glu298-asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100:1515-1520.
27. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109:1359-1365.
28. Zhang C, Lopez-Ridaura R, Hunter DJ, Rifai N, Hu FB. Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among U.S. diabetic men. Diabetes 2006; 55:2140-2147.
29. Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007; 121:169-178.
30. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37:84-89.
31. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. Glutamate at position 298. Proc Natl Acad Sci U S A 2000; 97:2832-2835.
32. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the glu(298) → asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276:26674-26679.
33. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase glu298asp polymorphic variants in human endothelial cells. Pharmacogenetics 2004; 14:831-839.
34. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 2001; 37:529-534.
35. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15:3-9.
36. Mayer BX, Mensik C, Krishnaswami S, Derendorf H, Eichler HG, Schmetterer L, et al. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-nmma in humans. Br J Clin Pharmacol 1999; 47:539-544.
37. Bech JN, Nielsen CB, Ivarsen P, Jensen KT, Pedersen EB. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans. Am J Physiol 1998; 274:F914-F923.
38. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97:22-28.
39. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229.
40. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 2000; 35:936-941.
41. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37:1351-1358.
42. Schaufele TG, Schlaich MP, Delles C, Klingbeil AU, Fleischmann EH, Schmieder RE. Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney Int 2006; 70:1177-1181.
43. Schlaich MP, Oehmer S, Schneider MP, Delles C, Schmidt BM, Schmieder RE. Effects of nitric oxide synthase inhibition and L-arginine on renal haemodynamics in young patients at high cardiovascular risk. Atherosclerosis 2007; 192:155-160.